GleamWall
中文EN

QDEL QuidelOrtho Corp

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1906324 · Fiscal year ends 01/01

Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.5%
TTM net income YoY68.7%
TTM EPS YoY69.0%
Revenue 3-yr CAGR-6.0%
Net income 3-yr CAGR—

Margins

Gross margin44.2%
Operating margin-4.9%
Net margin-14.2%
FCF margin-4.5%
EBITDA margin12.9%

Returns

ROE-19.3%
ROA-6.4%
ROIC (approx.)-2.2%
Asset turnover0.45x

Leverage & solvency

Liabilities / assets69.0%
Debt / equity1.64x
Current ratio1.36x
Interest coverage-0.60x

Cash quality & payout

Operating cash flow / net income-0.02x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue4.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-28FY20242024-12-29
Income statement
Revenue$2.73B$2.78B
Cost of revenue$1.46B$1.50B
Gross profit$1.27B$1.29B
R&D expense$186.20M$218.70M
SG&A expense$746.30M$766.80M
Operating income-$919.20M-$1.96B
Interest expense$177.60M$163.50M
Pretax income-$1.11B-$2.13B
Income tax$24.10M-$79.50M
Net income-$1.13B-$2.05B
EBITDA-$477.20M-$1.51B
EPS (basic)-16.69-30.54
EPS (diluted)-16.69-30.54
Weighted avg. shares (diluted)67.80M67.20M
Banking
Net interest income—-$163.50M
Balance sheet
Cash & equivalents$169.80M$98.50M
Short-term investments—$0
Receivables$417.00M$282.40M
Inventory$577.60M$533.70M
Current assets$1.45B$1.22B
PP&E, net$1.36B$1.38B
Goodwill$0$649.50M
Intangibles$2.56B$2.74B
Total assets$5.77B$6.42B
Current liabilities$966.10M$998.80M
Short-term debt$178.30M$341.80M
Long-term debt$2.47B$2.14B
Total debt$2.65B$2.48B
Total liabilities$3.85B$3.44B
Shareholders' equity$1.92B$2.98B
Net debt$2.48B$2.38B
Shares outstanding67.90M67.30M
Cash flow statement
Operating cash flow$105.20M$83.00M
Capital expenditure$188.20M$195.10M
Free cash flow-$83.00M-$112.10M
Investing cash flow-$192.70M-$149.90M
Financing cash flow$155.80M$48.80M
Depreciation & amortization$442.00M$453.40M
Stock-based compensation$45.90M$42.10M
Share buybacks$0$0

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.